Home › Trials › NCT04541810

Assessing the effects of Upadacitinib in Korean patients with various inflammatory conditions

Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib in Korean Patients

Observational AbbVie · NCT04541810

This study is testing if the oral medication Upadacitinib is safe and effective for Korean adults and teens with moderate to severe inflammatory conditions like rheumatoid arthritis and atopic dermatitis.

Quick facts

Study typeObservational
Enrollment3600 (estimated)
Ages12 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsupadacitinib
Locations116 sites (Busan, Busan Gwang Yeogsi and 115 other locations)
Trial IDNCT04541810 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the safety and effectiveness of oral Upadacitinib tablets in Korean participants suffering from moderate to severe active rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. The study aims to monitor adverse events and changes in disease symptoms among these patients. Participants must meet specific eligibility criteria, including being adults or adolescents suitable for Upadacitinib treatment as per local guidelines. The study is conducted at multiple locations in Busan, South Korea.

Who should consider this trial

Good fit: Ideal candidates include Korean adults aged 19 and older, and adolescents aged 12 and older with atopic dermatitis, who are eligible for Upadacitinib treatment.

Not a fit: Patients for whom Upadacitinib is contraindicated according to the approved local label may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the safety and efficacy of Upadacitinib for managing symptoms in patients with these inflammatory conditions.

How similar studies have performed: Other studies have shown promising results with Upadacitinib in treating similar inflammatory conditions, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult participants (\>= 19 years of age), Atopic dermatitis includes both adolescents (\>= 12 years of age) and adults.
* Participants suitable for the treatment with upadacitinib according to the approved local label.

Exclusion Criteria:

- Participants for whom the drug is contraindicated in the approved local label.

Where this trial is running

Busan, Busan Gwang Yeogsi and 115 other locations

+66 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Rheumatoid ArthritisAtopic DermatitisAnkylosing SpondylitisPsoriatic ArthritisUpadacitinibRINVOQ
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.